attunepharma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: /wp-admin/ Allow: | ||
Meta Tags
| Title | Attune |
| Description | About Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel oral once-daily small-molecule therapeutics for the treatment of rare |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 107.180.26.70 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
attunepharma.com Valuation
|
US$2,082,628
Last updated: 2023-05-07 14:25:36
attunepharma.com has Semrush global rank of 5,082,187. attunepharma.com has an estimated worth of US$ 2,082,628, based on its estimated Ads revenue. attunepharma.com receives approximately 240,304 unique visitors each day. Its web server is located in United States, with IP address 107.180.26.70. According to SiteAdvisor, attunepharma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$2,082,628 |
| Daily Ads Revenue | US$1,923 |
| Monthly Ads Revenue | US$57,673 |
| Yearly Ads Revenue | US$692,074 |
| Daily Unique Visitors | 16,021 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| attunepharma.com. | A | 7199 | IP: 107.180.26.70 |
| attunepharma.com. | NS | 3600 | NS Record: ns57.domaincontrol.com. |
| attunepharma.com. | NS | 3600 | NS Record: ns58.domaincontrol.com. |
| attunepharma.com. | MX | 600 | MX Record: 0 attunepharma-com.mail.protection.outlook.com. |
| attunepharma.com. | TXT | 600 | TXT Record: NETORGFT2465637.onmicrosoft.com |
| attunepharma.com. | TXT | 600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
HtmlToTextCheckTime:2023-05-07 14:25:36
| Attune Pharmaceuticals Team Programs Investors Media Contact Team Programs Investors Media Contact About Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases. Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More > Attune Pharmaceuticals 250 West 55 th Street, 34 th Floor New York, NY 10019 © Attune Pharmaceuticals. All Rights Reserved. Developed by Synergy |
HTTP Headers
HTTP/1.1 200 OK Date: Thu, 28 Oct 2021 05:08:00 GMT Server: Apache Vary: User-Agent,Accept-Encoding Upgrade: h2,h2c Connection: Upgrade Last-Modified: Tue, 18 Feb 2020 16:45:43 GMT Accept-Ranges: bytes Content-Length: 35612 Cache-Control: max-age=0, no-cache, no-store, must-revalidate Pragma: no-cache Expires: Mon, 29 Oct 1923 20:30:00 GMT Content-Type: text/html; charset=UTF-8 |
attunepharma.com Whois Information
Domain Name: ATTUNEPHARMA.COM Registry Domain ID: 2070970112_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2020-11-03T14:46:23Z Creation Date: 2016-11-02T14:31:31Z Registry Expiry Date: 2022-11-02T14:31:31Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS57.DOMAINCONTROL.COM Name Server: NS58.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-15T22:49:15Z <<< |